MedTrace Logo

Umbilical Cord Blood Mononuclear Cells Therapy in Liver Cirrhosis

NCT01942915 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2013-11-15

No results posted yet for this study

Summary

This study is to evaluate the safety and efficacy of umbilical cord blood mononuclear cells transplantation in liver cirrhosis patients.

Conditions

Interventions

BIOLOGICAL

Umbilical Cord Blood Mononuclear Cells

Participants will be transplanted with umbilical cord blood mononuclear cells.

Sponsors & Collaborators

  • Hebei Medical University

    lead OTHER

Principal Investigators

  • Baoyong Yan, doctor · The First Hospital of Hebei Medical University

  • Lixin Tong, master · The First Hospital of Hebei Medical University

  • Sui Zhang, master · The First Hospital of Hebei Medical University

  • Quanhai Li, doctor · The First Hospital of Hebei Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-12-31
Completion
2014-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01942915 on ClinicalTrials.gov